Lipton A - Search Results

1

Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.

Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Ali SM, et al. Among authors: lipton a. Clin Chem. 2002 Aug;48(8):1314-20. Clin Chem. 2002. PMID: 12142389 Clinical Trial.

2

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Lipton A, et al. J Clin Oncol. 2002 Mar 15;20(6):1467-72. doi: 10.1200/JCO.2002.20.6.1467. J Clin Oncol. 2002. PMID: 11896093 Clinical Trial.

3

Serum osteoprotegerin levels in healthy controls and cancer patients.

Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. Lipton A, et al. Clin Cancer Res. 2002 Jul;8(7):2306-10. Clin Cancer Res. 2002. PMID: 12114435

4

Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.

Witters L, Engle L, Lipton A. Witters L, et al. Among authors: lipton a. Oncol Rep. 2002 Nov-Dec;9(6):1163-6. Oncol Rep. 2002. PMID: 12375012

5

Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.

Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A. Witters LM, et al. Among authors: lipton a. Am J Clin Oncol. 2003 Feb;26(1):50-4. doi: 10.1097/00000421-200302000-00011. Am J Clin Oncol. 2003. PMID: 12576925

6

Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Carney WP, et al. Among authors: lipton a. Clin Chem. 2003 Oct;49(10):1579-98. doi: 10.1373/49.10.1579. Clin Chem. 2003. PMID: 14500583 Review.

7

Metastatic breast cancer: overview of treatment.

Ali SM, Harvey HA, Lipton A. Ali SM, et al. Among authors: lipton a. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S132-7. doi: 10.1097/01.blo.0000092981.12414.7b. Clin Orthop Relat Res. 2003. PMID: 14600603 Review.

8

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W. Lipton A, et al. Cancer. 2005 Jul 15;104(2):257-63. doi: 10.1002/cncr.21202. Cancer. 2005. PMID: 15952182 Free article.

9

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.

Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A. Souder C, et al. Among authors: lipton a. Cancer. 2006 Nov 15;107(10):2337-45. doi: 10.1002/cncr.22255. Cancer. 2006. PMID: 17048231 Free article. Clinical Trial.

10

Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W. Lipton A, et al. Cancer. 2007 May 15;109(10):1933-9. doi: 10.1002/cncr.22637. Cancer. 2007. PMID: 17407159 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

512 results

Search Page

Filters